US2019112581A1PendingUtilityA1

Host Cell Modification with Artificial Endosymbionts

Assignee: BELL BIOSYSTEMS INCPriority: Sep 3, 2013Filed: Dec 19, 2018Published: Apr 18, 2019
Est. expirySep 3, 2033(~7.1 yrs left)· nominal 20-yr term from priority
C07K 14/195C12N 2510/00C12N 5/16C12N 15/87C07K 2319/034C12N 1/20C07K 14/435
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell. The secreted polypeptide can be a selectable marker, a reporter protein, a transcription factor, a signal pathway protein, a receptor, a growth factor, a cytokine, an effector molecule or other factors that can produce a phenotype in the host cell.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . An isolated mammalian cell comprising a magnetotactic bacterium, wherein the magnetotactic bacterium provides a protein to the host cell and thereby provides a phenotype to the mammalian cell, and wherein the mammalian cell is a hematopoietic cell. 
     
     
         18 . The mammalian cell of  claim 17 , wherein the hematopoietic cell is a T-cell. 
     
     
         19 . The mammalian cell of  claim 17 , wherein the hematopoietic cell is a B-cell. 
     
     
         20 . The mammalian cell of  claim 17 , wherein the hematopoietic cell is a human cell. 
     
     
         21 . The mammalian cell of  claim 17 , wherein the hematopoietic cell is a rodent cell. 
     
     
         22 . The mammalian cell of  claim 17 , wherein the protein is a reporter. 
     
     
         23 . The mammalian cell of  claim 22 , wherein the reporter is a PET reporter or an optical reporter. 
     
     
         24 . The mammalian cell of  claim 18 , wherein the T-cell is a human T-cell. 
     
     
         25 . The mammalian cell of  claim 18 , wherein the hematopoietic cell is in a mammal. 
     
     
         26 . The mammalian cell of  claim 18 , wherein the hematopoietic cell is in a rodent.

Join the waitlist — get patent alerts

Track US2019112581A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.